aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: May 7, 2025
Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis on track for the third quarter of 2025.
Blinded baseline demographics and disease characteristics from Phase 3 EFZO-FIT™ study and current U.S. epidemiology and treatment practices for pulmonary sarcoidosis to be presented at ATS 2025.
Read more at globenewswire.com
